共 50 条
CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population
被引:1
|作者:
Carpi, Francesco M.
[1
]
Vincenzetti, Silvia
[2
]
Ubaldi, Jessica
[1
]
Pucciarelli, Stefania
[1
]
Polzonetti, Valeria
[1
]
Micozzi, Daniela
Micinini, Fiorenzo
[3
]
Napolioni, Valerio
[1
]
机构:
[1] Univ Camerino, Sch Biosci & Biotechnol, I-62032 Camerino, Italy
[2] Univ Camerino, Sch Vet Sci, I-62032 Camerino, Italy
[3] Univ Camerino, Sch Pharm & Hlth Prod, I-62032 Camerino, Italy
关键词:
cytidine deaminase;
diplotype;
enzyme activity;
HPLC;
polymorphism;
population variability;
whole blood;
HUMAN CYTIDINE DEAMINASE;
SINGLE-NUCLEOTIDE POLYMORPHISM;
HAPLOTYPE BLOCKS;
GEMCITABINE;
TOXICITY;
CYTARABINE;
VARIANTS;
PATIENT;
PHARMACOGENOMICS;
IDENTIFICATION;
D O I:
10.2217/PGS.13.56
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Aim: To assess the distribution of CDA activity from whole blood of 142 healthy subjects, determining its main predictors among genetic (six CDA SNPs) and physiological factors (age and gender). Moreover, we performed a kinetic study of the two CDA protein variants (Q27 and K27) determined by the rs2072671 SNP. Materials & methods: CDA activity was assessed by HPLC. Selected CDA SNPs were genotyped by PCR-based methods. Recombinant CDA protein variants (Q27 and K27) were expressed in an Escherichia coli strain S circle divide 5201 and kinetic assays were performed. Results: The mean value of CDA activity was 0.051 +/- 0.024 mU/mg and followed a normal distribution in the study population. Carriers of the CDA*2B (-451T/-92G/-31Del/79C/435C) haplotype displayed higher CDA activity compared with the others. CDA -451G>A, -92A>G and 79A>C (K27Q) SNPs displayed significant associations with CDA activity. The best predictive model of CDA activity included the variables gender and CDA 79A>C (K27Q). Cytidine is the preferential substrate for the variant Q27. Conclusion: We suggest the analysis of both CDA activity and CDA 79A>C (K27Q) SNP in future prospective trials with cytidine analogs, alone or in combination, in order to identify the best marker to secure the administration of these anticancer therapies. Original submitted 22 October 2012; Revision submitted 11 March 2013.
引用
收藏
页码:769 / 781
页数:13
相关论文